Aileron Therapeutics, Inc.ALRNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank92
5Y CAGR+16.2%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+16.2%/yr
Long-term compound
Percentile
P92
Near historical high
vs 5Y Ago
2.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 47.77% |
| Q2 2025 | 0.94% |
| Q1 2025 | 3.23% |
| Q4 2024 | 5.36% |
| Q3 2024 | -55.66% |
| Q2 2024 | 41.58% |
| Q1 2024 | -29.10% |
| Q4 2023 | 169.97% |
| Q3 2023 | 3.28% |
| Q2 2023 | -13.13% |
| Q1 2023 | -5.30% |
| Q4 2022 | 2.59% |
| Q3 2022 | -14.00% |
| Q2 2022 | 3.16% |
| Q1 2022 | 12.11% |
| Q4 2021 | -10.27% |
| Q3 2021 | 16.56% |
| Q2 2021 | -19.34% |
| Q1 2021 | 17.91% |
| Q4 2020 | -3.28% |
| Q3 2020 | 22.59% |
| Q2 2020 | -31.88% |
| Q1 2020 | 6.37% |
| Q4 2019 | -23.28% |
| Q3 2019 | 11.87% |
| Q2 2019 | -2.04% |
| Q1 2019 | 3.91% |
| Q4 2018 | -4.91% |
| Q3 2018 | -26.78% |
| Q2 2018 | 48.75% |
| Q1 2018 | 6.85% |
| Q4 2017 | 4.96% |
| Q3 2017 | 45.23% |
| Q2 2017 | 8.74% |
| Q1 2017 | 21.46% |
| Q4 2016 | -16.66% |
| Q3 2016 | -53.03% |
| Q2 2016 | 139.56% |
| Q1 2016 | 12.35% |
| Q4 2015 | -9.81% |